HUDSON, NY--(Marketwired) - Taconic, a global leader in the acquisition, custom generation, breeding, and distribution of genetically engineered mouse and rat research models, announced today the promotion of David T. Hansen to President of its Research Models and Services Division (RMS). In his new role as President, Mr. Hansen will spearhead efforts to manage Taconic's market leading position in providing genetically engineered models for drug discovery and preclinical development.
Mr. Hansen joined Taconic as Managing Director of Taconic Europe A/S in 2008. Within two years of taking the helm in Europe he grew European sales by 20% and increased the profitability of the RMS Division by over 10% in a challenging market. In 2010, Mr. Hansen was appointed Sr. Vice President of RMS at a critical time when Taconic was establishing its Strategic Business Unit structure. Mr. Hansen quickly built a strong management team within RMS and helped increase Taconic's leadership position in managing the acquisition and breeding of genetically engineered and humanized mice and rat models. Such research lines are key tools in translational research that seeks to increase the predictability of human response to pharmaceutical products and contribute to dramatic advances in treatments for patients suffering from cancer and other life altering diseases.
Samuel Phelan, Executive Chairman at Taconic, comments on the promotion of Mr. Hansen and the key role he will play as President: "Taconic continues to see growth in its portfolio of genetically engineered models and services as scientists worldwide seek to improve the predictability of human response to drugs by gaining important insights during drug discovery and preclinical development. Since he joined Taconic, David has been a key figure in the growth of this part of our business. As President of our RMS business unit David will play a leadership role in developing future alliances, joint ventures, and other relationships with biotechnology, pharmaceutical and life sciences firms worldwide."
Prior to joining Taconic, David was CEO of Novo Nordisk Scandinavia AB. Previously he was General Manager and Business Development Director for Novo Nordisk in the Czech Republic and Eastern Europe respectively. Mr. Hansen's 13+ year career with Novo Nordisk and 12+ years of experiences as founder and executive at NetDania give him extensive global sales and business development experience which will be applied to growing Taconic's business in Europe and Asia.
Headquartered in Hudson, NY, with facilities in the United States, Europe, and Asia, Taconic is a global leader in the provision of genetically engineered mouse and rat research models and services. As a full-service provider, founded in 1952, Taconic helps clients acquire, license, develop, breed, cryopreserve, prepare and distribute research lines worldwide. Taconic's products and services are used by over 1250 clients including many of the top 100 biopharmaceutical companies and leading academic research institutions worldwide. By supplying research-ready as well as custom-generated mice and rat models globally, Taconic assists scientists in their efforts to discover treatments and cures that advance human health.